Ultrasound sensitive (sonosensitive liposomes) are drug delivery systems designed for releasing their drug load upon exposure to ultrasound (US). Inclusion of dioleoylphosphatidylethanolamine (DOPE) in liposome membranes was previously shown to induce sonosensitivity. For efficient US mediated drug delivery to solid tumours, a long blood circulation time of the liposomal drug providing high tumour uptake is required. In this study, blood pharmacokinetics of DOPE-based liposomal doxorubicin (DXR) were evaluated in mice. A markedly faster blood clearance of DXR was observed for DOPE-rich liposomes compared to Caelyx! (standard liposomal DXR). Subsequently, liposome membrane composition was altered to improve drug retention in the bloodstream, while maintaining sonosensitivity. Formulations with reduced blood clearance of DXR were obtained by reducing the content of DOPE from 62 to 32 or 25 mol%. These formulations showed long blood circulation time, as approximately 20% of the administered DXR dose was present in the bloodstream 24 h after intravenous injection. The reduction in liposomal DOPE content did not significantly reduce US mediated DXR release in vitro, indicating that DOPE is a potent modulator to sonosensitivity. The novel liposome formulations, containing moderate amounts of DOPE, displayed similar blood pharmacokinetic profiles as standard liposomal DXR, but a markedly improved sonosensitivity.
INTRODUCTION
Liposomes that exhibit controlled release properties have potential for delivery of chemotherapeutic drugs to solid tumours. Ideally, liposomes should accumulate intact at the tumour site, and subsequently release their drug load. The extent of liposome accumulation in the tumour is largely determined by the blood circulation time of the liposomal drug, where liposomes that retain their drug over several hours to days will provide greater tumour delivery and less non-specific toxicity. For reviews see Drummond et al., 1999; Gabizon et al., 2003 . After liposome accumulation within the tumour tissue, the encapsulated drug must be released before it can be taken up by the neoplastic cells (Horowitz et al., 1992) . In the case of long circulating PEGylated doxorubicin (DXR)-liposomes, the drug has shown to leak slowly from the liposome (Horowitz et al., 1992; Colbern et al., 2000) . Thus, triggered destabilization of the liposome carrier within the tumour area might lead to a substantial increase in drug availability and thus improved therapeutic efficacy.
Recently, there has been increasing interest in using ultrasound (US) as a means to physically and non-invasively trigger drug release from liposomes upon accumulation in tumour tissue (de Smet et al., 2010; Schroeder et al., 2009; Myhr and Moan, 2006; Pong et al., 2006) . Local application of US to tumours produces several effects, such as enhancing extravasation of liposomes to tumours, inducing drug leakage from the liposome carrier and enhancing cell membrane permeability with a resulting increased intracellular drug uptake (For recent reviews see Schroeder et al., 2009; Pitt et al., 2004; Frenkel, 2008) . In order to maximize the therapeutic efficacy, liposomes should display properties that both impart high US sensitivity (sonosensitivity) and favour drug retention in the blood stream, to enable sufficient tumour accumulation. Several studies have shown that gas-containing particles are highly sonosensitive (Huang et al., 2008; Unger et al., 1998; Huang and MacDonald., 2004) . Unfortunately, gas-filled liposomes are micron-sized and thus too large to allow for effective extravasation into tumour tissue (Ferrara, 2008; Maeda et al., 2000) . Another limitation of such particles is the rapid dissolution of the entrapped gas in blood circulation with consequent loss of sonosensitivity (Unger et al., 1998; Ferrara, 2008 ).
An approach to formulate gas-free liposomes combining high sonosensitivity with long blood circulations times might be to modulate the liposome membrane composition.
Previously, we demonstrated that PEGylated liposomes comprising phosphatidylethanolamine showed a several fold increase in drug release compared to Caelyx! (standard liposomal DXR) during in vitro exposure to US Evjen et al., 2011a; Evjen et al., 2011b ). An US enhanced therapeutic activity of DSPE-based liposomal DXR was demonstrated in tumoured mice (Hagtvet et al., 2010) . Recently, we ! "! found that liposomes based on DOPE as the main phospholipid constituent displayed markedly improved sonosensitivity than DSPE-based liposomes (Evjen et al., 2011a) . These DOPE-based liposomes, however, were not evaluated and optimized as drug carriers for in vivo applications.
In the present study, blood circulation time of various DXR-containing liposome formulations combining DOPE with distearoylphosphatidylcholine (DSPC), PEGylated distearoylphosphatidylethanolamine (DSPE-PEG 2000) and cholesterol, were investigated in non-tumoured mice. Novel formulations combining high sonosensitivity and long blood residence time of DXR were obtained. For anaesthesia of mice a mixture of 2.4 mg/ml tiletamine and 2.4 mg/ml zolazepam (Zoletil ® vet, Virbac Laboratories, Carros, France), 3.8 mg/ml xylazine (Narcoxyl ® vet, Roche, Basel, Switzerland) and 0.1 mg/ml butorphanol (Torbugesic ® , Fort Dodge Laboratories, Fort Dodge, IA) was prepared and used.
MATERIALS AND METHODS

Materials
Liposome preparation
Liposomes with different mol % of the lipids DOPE, DSPC, DSPE-PEG and cholesterol were prepared by the thin film hydration and sequential extrusion method similarly as previously described (Evjen et al., 2011a The mean target size of the liposomes was 85 ± 5 nm.
DXR was remote loaded into liposomes using an ammonium sulfate transmembrane gradient (Haran et al., 1993) , as previously described by Evjen et al., 2011a . The resulting nominal lipid and DXR concentrations were 16 mg/ml and 1 mg/ml, respectively.
Liposome characterization
The mean intensity-weighted hydrodynamic liposome diameter was determined by Photon Correlation Spectroscopy (Nanosizer, Malvern Instruments, Malvern, UK). The Determination of liposomal entrapment efficiency of DXR was estimated by fluorescence measurements as previously described (Evjen et al., 2011) . All liposome formulations displayed entrapment efficiencies of DXR of more than 95% (drug:lipid ratio 1:16 wt/wt).
Ultrasound mediated drug release
US release measurements were conducted using a 40 kHz US transducer (VC 750, Sonic and Materials, Inc, Newtown, CT, USA) with a 19 mm diameter nonfocused probe mounted in a custom-built sample chamber as previously described . In brief, the liposome dispersions were diluted in a 1:500 (v/v) ratio with sucrose/HEPES solution containing 20% serum, just prior to the US experiments. The diluted liposome dispersions were exposed to 40 kHz US at a nominal intensity of 12 W/cm 2 in a continuous mode (100 % duty cycle) up to 6 min. Acoustic pressure measurements conducted with a Bruel and Kjaer hydrophone (Type 8103, Denmark) in the sample chamber gave 240 kPa (pk-pk). The temperature in the liposome samples never exceeded 30 °C during the US experiments, excluding the possibility of direct thermal effect of US on liposomal drug release.
DXR release could be monitored due to the relief of DXR-mediated fluorescence self-quenching in the external liposomal phase, and concomitant increase in fluorescence
intensity. An optical fiber probe (Ocean optics, type QP600-2-VIS/BX, Florida, USA) was ! "! used to measure in line the increase in fluorescence intensity as a result of DXR release, using the following equation:
Where F 0 and F t are the fluorescence intensities of a given liposome sample prior to and after a given duration (t) of US respectively, and F max is the fluorescence intensity after liposome solubilisation with surfactant (Triton-X 100). The diluted liposome samples were solubilised with Triton-X 100 at a ratio of 100:1 (v/v). Fluorescence intensity measurements were performed using a fluorescence spectrometer from Ocean Optics (model QE65000. Duiven, Netherlands). The excitation and emission wavelength for DXR were 488 and 595 nm, respectively. Triplicate samples were measured.
Serum stability assay
Liposome stability in vitro was studied using a well-established serum-induced leakage assay as previously described by Evjen et al., 2010 . Triplicate samples were measured.
Pharmacokinetic and biodistribution studies in non-tumoured mice
Male atymic nude Balb/c mice were provided by the Department of Comparative Medicine (animal facility), the Norwegian Radium Hospital. The mice were housed in transparent boxes with bedding material, fed ad libitum and kept under specific pathogen-free conditions. The temperature and relative humidity were kept constant at 20-21°C and 60%, respectively. At the end of the experiments all animals were euthanized by cervical dislocation. All procedures were performed according to protocols approved by the National (Drummond et al., 1999) .
The liposomes were injected intravenously (i.v.) into the tail vein under anaesthesia induced by subcutaneous administration of 0.1 ml anaesthetic agent. Animals were sacrificed in groups of three at different time points post injection (0.5, 1, 3, 8 12, 24, 48 h). Blood samples were obtained by cardiac puncture using heparinized syringes and stored in heparinized tubes. Liver, spleen and kidneys were excised and their weight registered. All blood and tissue samples were kept on ice bath until storage at -80 °C.
Quantification of DXR was performed similarly as described by Gabizon et al., 1989. In brief, 0.1 ml of whole blood samples (lysed due to freezing) was mixed with 1. quantified by fluorescence measurements as previously described using multipoint standard curves. The latter were generated by adding known amounts of standard liposomal DXR to blood and tissue (liver, spleen and kidney) homogenate and incubated and centrifuged as described above. All calibration curves had regression coefficients (R 2 )>0,99.
Statistics
All data are reported as mean values with standard deviation. Statistical comparison of the DXR concentration in blood and organs for the different liposome formulations was performed at each time point post injection using a student t-test with p<0.05.
RESULTS
Blood pharmacokinetics of prototype DOPE-based liposomes
DOPE-based liposomes with membrane composition DOPE:DSPC:DSPE-PEG 2000:CHOL 62:10:8:20 mol% were previously demonstrated to release their DXR load almost completely during 4 minutes of US exposure in vitro (Evjen et al., 2011) .
Furthermore these liposomes showed negligible leakage of DXR during 24 h in vitro incubation in sucrose/HEPES solution containing 20% serum at 37 °C (Evjen et al., 2011) .
! "!
Hence, this DOPE-based formulation was first selected for assessment of blood pharmacokinetics in mice. Blood levels of DXR provide a good indication of liposomal drug retention, since DXR released in the bloodstream is rapidly distributed to other tissues and organs (Gabizon et al., 1989) . (Fig 1) . ! "!
Effect of lipid composition on DXR blood pharmacokinetics of DOPE-based liposomes
Further, both blood clearance kinetics and in vitro sonosensitivity for a range of DOPE-based formulations with different lipid composition were investigated. Unsaturated phospholipids, like DOPE, fluidize the liposome membrane thereby increasing the membrane permeability at physiological temperature due to their low gel-to-liquid-crystalline phase transition temperature (T c ) (Demel et al., 1976) . Previous studies have shown that addition of cholesterol to liposomes rigidifies the bilayer and reduces leakage of entrapped material at temperatures above the T c of the membrane (Gregoriadis, 1988; Damen et al., 1981; Ishida et al., 2006) .
In an attempt to prolong blood circulation time of DOPE-containing liposomal DXR, membrane composition was altered by both increasing the level of cholesterol and reducing the level of DOPE. An overview of the different formulations produced is presented in Table   1 .
Note that all formulations were comparable in terms of mean size and drug-to-lipid ratio, and differed only in membrane composition. The comparable liposome size was essential to better assess the influence of the membrane composition per se on blood circulation time and biodistribution. In vitro leakage studies showed no detectable leakage of DXR from the liposomes during the course of 24 h incubation in 20% serum at 37 ºC. At a constant DOPE level of 52 mol% no change in blood clearance were observed for liposomes containing different cholesterol levels up to 40 mol% (formulation no 1-4) (Fig   2) . In contrast, liposomal DXR containing an intermediate level of DOPE (32 and 25 mol%, respectively), and consequently an increased level of DSPC (20 and 27 mol%, respectively), showed a significant prolonged circulation time (Fig 3) . The blood clearance profiles of DXR (Fig 3) . 
Effect of lipid composition on biodistribution of DOPE-containing liposomal DXR
If the relatively faster blood clearance of DXR for DOPE-rich liposomes was a consequence of carrier recognition by the mononuclear phagocyte system (MPS), then a corresponding increased accumulation in liver and spleen would be expected. Hence, DXR levels in liver, spleen and kidneys were investigated for two formulations comprising 32 and 52 mol% DOPE, respectively (no 4 and 5). These two formulations, herein termed intermediatelevel and highlevel DOPE-containing liposomes, showed a relatively slow and fast blood clearance of DXR, respectively (Fig 2 and 3) .
No significant differences in DXR concentration in spleen could be observed for the intermediate and highlevel DOPE formulations (Fig 4B) . The data revealed a slightly lower DXR concentration in liver for the highlevel DOPE-containing liposomes (Fig 4A) . However, the difference was only significant at 12 h and 48 h post injection, p<0.05 (Fig 4A) . Thus, the faster blood clearance profile of DXR for this formulation most likely reflected leakage of DXR from the liposome carrier, and not an increased uptake by the MPS.
! ""!
Moreover, for the highlevel DOPE-containing liposomes, DXR levels in kidneys reached a maximum 12 h after injection. The intermediatelevel DOPE-containing liposomes showed sustained levels of DXR throughout the course of the experiment (Fig 4C) . This pattern may reflect slow release of DXR from the intermediatelevel DOPE-containing liposomes in blood circulation, as indicated in Figs 2 and 3, resulting in higher DXR concentrations in the kidneys at the later time-points (Fig 4C) . 
Effect of DOPE level on sonosensitivity
Variations in lipid membrane composition are shown to influence sonosensitivity of liposomes (Pong et al., 2006; Schroeder et al., 2009; Evjen et al., 2010a; Evjen et al., 2010b; Lin et al., 2001) . We recently demonstrated that incorporation of DOPE into liposome bilayers drastically enhanced sonosensitivity compared to DSPE-based liposomes and standard liposomal DXR, respectively (Evjen et al., 2011a) . The minimum amount of DOPE required for maintaining an acceptable sonosensitivity in vitro, however, was not explored. between 25 and 52 mol% DOPE (Fig 5) . These formulations showed up to a 7-fold increase in DXR release extent when compared to standard liposomal DXR after 6 min US exposure.
Poor sonosensitivity was observed for liposomes composed of 12 mol% DOPE, as evidenced by a significant reduction in DXR release (Fig 5) . (2) leakage of the entrapped drug from the liposomes in blood circulation. In general, small
PEGylated liposomes below 100 nm in diameter, as described in the current study, are to a certain extent able to escape the MPS, which in turn provides prolonged blood circulation time of the liposome carrier and consequently increased accumulation within tumour tissue.
For reviews see Drummond et al., 1999; Gabizon et al., 2003. For successful drug delivery, it is required that the liposomes are able to retain the entrapped drug in blood circulation en route to the tumour tissue.
! "#!
The liposomes comprising high levels of DOPE (62 and 52 mol%) showed relatively faster blood clearance of DXR than standard liposomal DXR (Fig 1) . This finding may reflect leakage of DXR from the liposome carrier due to high membrane permeability and consequent distribution to other tissues, and/or premature uptake of the DOPE-rich liposomes by the MPS. The DOPE-based liposomes showed no in vitro DXR leakage in 20% serum.
However, the stability in vitro may not always reflect liposomal drug retention in vivo, due to e.g. differences in the composition of bovine serum and mice blood. Discrepancy between in vitro and in vivo leakage results has previously been observed (Charrois and Allen., 2004; Mayer et al., 1990) .
Previous studies have demonstrated faster blood clearance kinetics of liposomal drugs composed of fluid lipids as a consequence of drug leakage (Charrois et al., 2004 , Gabizon et al., 1988 Gabizon et al., 1993 ., Ishida et al., 2006 . The permeability of liposome bilayers is to a great extent modulated by the T c of the phospholipids and the presence of cholesterol (Gabizon et al., 2003) . DOPE has a T c of -16 °C (Cullis et al., 1978) , resulting in highly fluid membranes at physiological temperature that are more permeable to molecules and ions. A partial loss of transmembrane ion-gradient might account for an elevated percentage of nonionized DXR in the liposome interior and subsequently DXR leakage.
Furthermore, a correlation between liposome permeability, lipid phase transition and cholesterol content has been established previously (Papahadjopoulos, 1996; Demel et al., 1976) . In general, cholesterol is known to improve the physical stability of PC-based liposomes by tightening the lipid membrane, reducing its permeability and consequently leakage of entrapped drug (Demel et al., 1976) . It was therefore interesting to note that no prolonged blood circulation time was obtained by increasing the cholesterol level from 20 to 40 mol% in DOPE-rich liposomes. The lack of any cholesterol stabilizing effect might be related to membrane packing constrains such as inhomogeneous distribution of cholesterol within the lipid membranes and/or poor cholesterol-phospholipid interactions, leading to high membrane permeability (Demel et al., 1976) .
When the DOPE level in liposomes was reduced to 32 mol% or below, the amount of DSPC in the membrane was consequently increased. The significantly prolonged blood circulation time of DXR for these formulations was probably both a result of reduced levels of DOPE and increased levels of DSPC. Previous studies have shown that saturated phosphatidylcholine provides order and rigidity to fluid-like lipid membranes and prolongs the blood residence time of liposomal drugs due to reduced leakage from the carrier (Demel et al., 1976; Charrois et al., 2004; Gabizon et al., 1988; Ishida et al., 2006; Senior et al., 1982) . There is a well-established correlation between long blood circulation time and increased liposome accumulation in tumours (Gill et al., 1995) . Hence, the prolonged blood circulation time for the 25 and 32 mol% DOPE-containing liposomes should provide a good basis for efficient tumour accumulation. To enable full availability of DXR to tumour cells, the DOPE-containing liposomes should be sufficiently destabilized by US at the tumour site.
Interestingly, the in vitro sonosensitivity of liposomes was largely maintained down to a level of 25 mol% DOPE. This particular formulation, comprising DOPE:DSPC:DSPE-PEG:cholesterol 25:27:8:40 mol%, showed approximately 70% release of DXR after 6 min US exposure in 20% serum. The results suggest that DOPE is a very potent sonosensitivity modulator, as only small amounts of the lipid were required to achieve efficient US mediated drug release. The DOPE-liposomes represented a several fold improvement in sonosensitivity compared to DSPE-based liposomal DXR and standard liposomal DXR, respectively (Hagtvet et al., 2010; Evjen et al., 2011) .
The US regime used in the current study (4 min 40 kHz US) is recently reported to induce a significant tumour regression in mice receiving DSPE-based liposomes, without inducing any acute toxicity (Hagtvet et al., 2010) . However, for further preclinical and clinical studies of DOPE-containing liposomes a more sophisticated US device enabling increased focusing ability to tumours may be preferred. This will be accomplished by using high frequency focused US probes. However, previous studies have shown that sonosensitivity of the liposomes are comparable using 40 kHz and 1.13 MHz US (Evjen et al., 2011b) .
In conclusion, novel sonosensitive and long-circulating DXR-liposomes containing DOPE were developed by optimising the membrane composition. Low or moderate amounts of DOPE were required to obtain a sufficiently long blood circulation time after i.v. injection in mice. This reduction in DOPE level did not adversely affect sonosensitivity. Further studies are required to establish whether the novel formulations in combination with US improve DXR delivery to tumour cells enhancing the therapeutic index.
